BrightSpring Health Services, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BTSG in the last 30 days.
See all $BTSG insider activity →BrightSpring Health Services (BTSG) generates 80% of revenue from specialty and institutional pharmacy services, with a strong structural moat due to low patient churn and recurring revenue. The company's 2026 outlook suggests it may be 10% undervalued, according to the analysis.
BrightSpring Health Services (BTSG) shares rose 4.8% after BMO Capital analyst Sean Dodge reaffirmed an Outperform rating and $70 price target. The stock is volatile, with 16 moves over 5% in the past year. Q2 revenue grew 23% YoY to $3.87B, with non-GAAP EPS of $0.45, beating expectations. The company is up 56.3% YTD but trades 17.7% below its 52-week high.
Greenwell Scott A. (President, PharMerica) sold 15,099 shares of BrightSpring Health Services, Inc. (BTSG) at $57.91 ($0.87M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BTSG (BrightSpring Health Services, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BTSG coverage spans earnings, financial news and market movers.
No immediate price impact expected as the piece offers only a descriptive overview.
Analyst reaffirmation drives buying pressure.
The insider sale may signal reduced confidence and could exert slight downward pressure on the stock.
Robust earnings beat and higher guidance indicate strong upside.
Strong earnings beat and raised guidance suggest upside potential, especially given the 59% YTD rally.
AlphAI scores every news story that mentions BTSG with an AI model for sentiment and relevance, and aggregates insider trades from BrightSpring Health Services, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BrightSpring Health Services (BTSG) generates 80% of revenue from specialty and institutional pharmacy services, with a strong structural moat due to low patient churn and recurring revenue. The company's 2026 outlook suggests it may be 10% undervalued, according to the analysis.
1 min readBrightSpring Health Services (BTSG) shares rose 4.8% after BMO Capital analyst Sean Dodge reaffirmed an Outperform rating and $70 price target. The stock is volatile, with 16 moves over 5% in the past year. Q2 revenue grew 23% YoY to $3.87B, with non-GAAP EPS of $0.45, beating expectations. The company is up 56.3% YTD but trades 17.7% below its 52-week high.
1 min readGreenwell Scott A. (President, PharMerica) sold 15,099 shares of BrightSpring Health Services, Inc. (BTSG) at $57.91 ($0.87M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readAPi Group (APG) reported Q2 2026 revenue of $2.3B, up 13.3% YoY, and raised full-year guidance. Analysts see 31% upside to $52.40. BrightSpring Health (BTSG) saw Q2 revenue rise 23% to $3.9B, lifted guidance, and has a 30% upside to $78.25.
3 min readBrightSpring Health Services (BTSG) stock has risen 59% YTD, outperforming industry and S&P 500. Q2 2026 revenues grew 23% to $3.9B, adjusted EBITDA up 44%. Growth driven by Specialty Pharmacy and Provider Services, with AI/automation improving efficiency. Leverage reduced to 2.15x. 2026 EPS estimates raised to $1.78 (78% growth). Risks include execution challenges and reimbursement pressures.
3 min readZacks says BrightSpring Health Services (BTSG) has growth momentum in Provider Services and Pharmacy Solutions, citing Q2 2026 Pharmacy Solutions revenue up 30% YoY to $2.9B and Provider Services up 30% to $466M. It also flags IRA reimbursement pressure, estimating about $50M impact in Q2 2026 and ~$200M full-year. BTSG shares are up 54.6% YTD; forward P/E 41.80.
7 min readBrightSpring Health Services (BTSG) reported Q2 revenue of $3.87B vs $3.66B expected and adjusted EPS of $0.45 vs $0.40, with adjusted EBITDA of $205.5M. The company raised full-year revenue guidance to $15.26B and EBITDA guidance to $832.5M. Management cited 30% Specialty and Infusion revenue growth and 31% script growth, while Home and Community Pharmacy faced customer exits and regulatory headwinds.
6 min readBrightSpring Health Services (BTSG) beat Q2 expectations with adjusted EPS of 45 cents (21.6% above consensus) and revenue of $3.87B (+23% YoY). It raised 2026 guidance to $15.10-$15.425B revenue and $820-$845M adjusted EBITDA. Specialty and infusion grew 30.1% and home health revenues rose 30.3%, while pharmacy fell 8% due to IRA impacts.
6 min readBrightSpring Health Services (BTSG) reported Q2 revenues of $3.87B, up 23% YoY, and adjusted EPS of 45 cents, up 104.5%, beating Zacks estimates, and raised its full-year outlook. The article cites gross margin at 12.7% (+80 bps) and operating margin up 180 bps. It notes forward P/E of 30.7x and expects IRA reimbursement impacts of about $45M per quarter in 2026.
6 min readBrightSpring Health Services (BTSG) shares fell 18.1% over the past week after better-than-expected Q2 results and raised guidance. Q2 revenue rose 23% to $3.87B and adjusted EPS rose 104.5% to 45 cents. 2026 guidance was raised to $15.1-$15.425B revenue and $820-$845M adjusted EBITDA, but investors cited valuation risk and policy-driven reimbursement pressure.
6 min read
